Page 353 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 353
LP05 DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT LATE BREAKER ePOSTERS
LP06 RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE
LP07 3 INFECTION: INTERIM ANALYSIS OF A FRENCH
LP08 MULTICENTER COMPASSIONATE USE PROGRAM
Christophe Hezode*, Victor De Ledinghen, Helene Fontaine,
Fabien Zoulim, Pascal Lebray, Nathalie Boyer, Dominique Larrey,
Christine Silvain, Danielle Botta-Fridlund, Vincent Leroy,
Marc Bourliere, Louis D’alteroche, Isabelle Hubert-Fouchard,
Dominique Guyader, Isabelle Rosa, Eric Nguyen-Khac,
Vincent Di Martino, Fabrice Carrat, Larysa Fedchuk, Raoudha Akremi,
Yacia Bennai, Jean-Pierre Bronowicki, France
SUSTAINED VIROLOGIC RESPONSE AFTER ACH-3102 AND
SOFOSBUVIR TREATMENT FOR 8 OR 6 WEEKS: A PHASE 2
“PROXY” STUDY
Ed Gane*, Christian Schwabe, Michael Mader, Vithika Suri,
Mary Donohue, Mingjun Huang, James Hui, Joanna Yang,
Heather Robison, David Apelian, Hetal Kocinsky, New Zealand
SIMEPREVIR (SMV) PLUS DACLATASVIR (DCV)
AND SOFOSBUVIR (SOF) IN TREATMENT-NAÏVE
AND -EXPERIENCED PATIENTS WITH CHRONIC
HEPATITIS C VIRUS GENOTYPE 1 OR 4 INFECTION AND
DECOMPENSATED LIVER DISEASE: INTERIM RESULTS
FROM THE PHASE II IMPACT STUDY
Eric Lawitz*, Fred Poordad, Julio Gutierrez, Thomas Kakuda,
Gaston Picchio , Guy De La Rosa, Greet Beets, Ann Vandevoorde,
Pieter Van Remoortere, Bert Jacquemyn, Gemma Quinn, Donghan Luo,
Sivi Ouwerkerk-Mahadevan, Leen Vijgen, Veerle Van Eygen,
Maria Beumont, The United States
SAFETY AND EFFICACY OF SOFOSBUVIR-CONTAINING
REGIMENS IN HEPATITIS C INFECTED PATIENTS WITH
REDUCED RENAL FUNCTION: REAL-WORLD EXPERIENCE
FROM HCV-TARGET
Varun Saxena*, Farrukh M. Koraishy, Meghan Sise, Joseph K. Lim,
Raymond T. Chung, Annmarie Liapakis, David R. Nelson,
Monica Schmidt, Michael W. Fried, Norah Terrault, The United States
Vienna, Austria • April 22–26, 2015 353
LP06 RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE
LP07 3 INFECTION: INTERIM ANALYSIS OF A FRENCH
LP08 MULTICENTER COMPASSIONATE USE PROGRAM
Christophe Hezode*, Victor De Ledinghen, Helene Fontaine,
Fabien Zoulim, Pascal Lebray, Nathalie Boyer, Dominique Larrey,
Christine Silvain, Danielle Botta-Fridlund, Vincent Leroy,
Marc Bourliere, Louis D’alteroche, Isabelle Hubert-Fouchard,
Dominique Guyader, Isabelle Rosa, Eric Nguyen-Khac,
Vincent Di Martino, Fabrice Carrat, Larysa Fedchuk, Raoudha Akremi,
Yacia Bennai, Jean-Pierre Bronowicki, France
SUSTAINED VIROLOGIC RESPONSE AFTER ACH-3102 AND
SOFOSBUVIR TREATMENT FOR 8 OR 6 WEEKS: A PHASE 2
“PROXY” STUDY
Ed Gane*, Christian Schwabe, Michael Mader, Vithika Suri,
Mary Donohue, Mingjun Huang, James Hui, Joanna Yang,
Heather Robison, David Apelian, Hetal Kocinsky, New Zealand
SIMEPREVIR (SMV) PLUS DACLATASVIR (DCV)
AND SOFOSBUVIR (SOF) IN TREATMENT-NAÏVE
AND -EXPERIENCED PATIENTS WITH CHRONIC
HEPATITIS C VIRUS GENOTYPE 1 OR 4 INFECTION AND
DECOMPENSATED LIVER DISEASE: INTERIM RESULTS
FROM THE PHASE II IMPACT STUDY
Eric Lawitz*, Fred Poordad, Julio Gutierrez, Thomas Kakuda,
Gaston Picchio , Guy De La Rosa, Greet Beets, Ann Vandevoorde,
Pieter Van Remoortere, Bert Jacquemyn, Gemma Quinn, Donghan Luo,
Sivi Ouwerkerk-Mahadevan, Leen Vijgen, Veerle Van Eygen,
Maria Beumont, The United States
SAFETY AND EFFICACY OF SOFOSBUVIR-CONTAINING
REGIMENS IN HEPATITIS C INFECTED PATIENTS WITH
REDUCED RENAL FUNCTION: REAL-WORLD EXPERIENCE
FROM HCV-TARGET
Varun Saxena*, Farrukh M. Koraishy, Meghan Sise, Joseph K. Lim,
Raymond T. Chung, Annmarie Liapakis, David R. Nelson,
Monica Schmidt, Michael W. Fried, Norah Terrault, The United States
Vienna, Austria • April 22–26, 2015 353
